| Trial ID: | L0536 |
| Source ID: | NCT05719714
|
| Associated Drug: |
Dapagliflozin 10 Mg [Farxiga]
|
| Title: |
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Diseases|Heart Failure with Preserved Ejection Fraction|Kidney Diseases|Heart Failure
|
| Interventions: |
DRUG: Dapagliflozin 10 MG [Farxiga]
|
| Outcome Measures: |
Primary: Left ventricular longitudinal strain (LVLS), 2D-speckle tracking echocardiography, 6 months|Peak VO2 (oxygen consumption), Cardiopulmonary exercise stress test, 6 months|Circulating plasma metabolite concentrations, Plasma, 6 months | Secondary: Left Atrial Reservoir Strain (LARS), 2D-STE, 6 months|Right ventricular free wall strain, 2D-STE, 6 Months
|
| Sponsor/Collaborators: |
Sponsor: Northwestern University | Collaborators: National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1|PHASE2
|
| Enrollment: |
60
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2024-01-16
|
| Completion Date: |
2026-09-30
|
| Results First Posted: |
|
| Last Update Posted: |
2025-04-01
|
| Locations: |
Northwestern University, Chicago, Illinois, 60607, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT05719714
|
